Start the conversation
Ekso Bionics Holding (OTCBB: EKSO) released a positive earnings report on March 17. Total revenue for the fourth quarter of 2014 was $1.5 million, up 87.5% from the $0.8 million achieved in Q4/2013. The surge in revenue was broad-based: revenue from EKSO’s medical devices was up from $0.5 million to $0.9 million, an improvement of 80%. Engineering services revenue was up 100% year-over-year, from $0.3 million to $0.6 million. Shipments also continue to surge, with 250% more devices shipped in 2014 than 2013.
By March 25, 2015, the financial analyst firm Sterne Agee became the second firm this year to issue a “Buy” rating for EKSO. Responding to the phenomenal revenue growth the company is seeing, Sterne Agee set a price target of $1.75 for EKSO. That 19% gain is very conservative compared to the 138% gain that the firm Ladenburg Thalmann is forecasting, with its price target of $3.50/share.